相关实验视频
Updated: May 6, 2026

07:29
Intravascular Delivery of Biologics to the Rat Kidney
Published on: September 1, 2016
7.5K
对于患有慢性疼痛和阿片类药物使用障碍或阿片类药物滥用的住院患者的低剂量布普伦诺芬启动:开放标签,并行组,有效性实施随机对照试验的协议
Benjamin T Hayes1, Guillermo Sanchez Fat1, Kristine Torres-Lockhart1
1Division of General Internal Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA.
Substance use & addiction journal
|July 28, 2024
概括
低剂量布普伦诺芬的开始可能会缓解阿片类药物使用障碍 (OUD) 和慢性疼痛 (CP) 的治疗. 这项研究将住院患者的低剂量与标准布普伦诺芬启动进行比较,以评估有效性和安全性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
- 实施科学 实施科学
背景情况:
- 布普伦诺芬有效治疗阿片类药物使用障碍 (OUD) 和慢性疼痛 (CP).
- 从完全阿片类药物激动剂过渡到布普伦诺芬可能是具有挑战性的.
- 低剂量布普伦诺芬的启动显示出希望,但缺乏严格的比较试验,特别是在医院环境中.
研究的目的:
- 为了比较低剂量与标准布普伦诺芬启动方案的有效性和安全性.
- 评估在医院环境中实施低剂量布普伦诺芬启动的实施情况.
- 评估患者对OUD和CP的结果,包括治疗吸收,安全性,可接受性和成本效益.
主要方法:
- 一个务实的,开放的,混合型I有效性-实施随机对照试验.
- 270名患有CP和OUD或阿片类药物滥用的住院患者被随机分类.
- 参与者接受了为期5天的低剂量或标准布普伦诺芬启动方案.
主要成果:
- 主要结局:在注册后7天接受布普伦诺芬治疗.
- 二次结果:OUD和CP结果在1,3个月和6个月.
- 收集了关于安全性,实施忠实性,患者接受度和成本效益的额外数据.
结论:
- 这项随机临床试验将提供关于低剂量布普伦诺芬启动疗法的有效性和安全性的最终数据.
- 这些发现将为不断发展的临床指南提供信息,建议布普伦诺芬用于CP.
- 该研究解决了对复杂患者群体的布普伦诺芬启动策略的理解的关键差距.
相关概念视频
Analgesia and Pain Management
3.4K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.4K
Opioid Analgesics: Morphine and Other Natural Cogeners
1.7K
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
1.7K
Opioid Analgesics: Synthetic and Semisynthetic Opioids
1.6K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.6K
Oral Drug Delivery Systems: Continuous-Release Systems
323
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
323

